Alnylam Pharmaceuticals
ALNY
#803
Rank
A$44.06 B
Marketcap
A$329.28
Share price
-1.38%
Change (1 day)
-53.98%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): A$1.65 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$4.80 Billion. In 2025 the company made an earning of A$0.93 Billion, an increase over its 2024 earnings that were of -A$0.34 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.65 B77.84%
2025 A$0.93 B-375.96%
2024 -A$0.34 Billion-24.59%
2023 -A$0.45 Billion-67.84%
2022 -A$1.4 Billion36.93%
2021 -A$1.02 Billion-8.04%
2020 -A$1.11 Billion-15.66%
2019 -A$1.32 Billion12.23%
2018 -A$1.17 Billion62.91%
2017 -A$0.72 Billion17.78%
2016 -A$0.61 Billion43.44%
2015 -A$0.43 Billion60.69%
2014 -A$0.27 Billion98.2%
2013 -A$0.14 Billion
2011 -A$78.67 Million27.48%
2010 -A$61.71 Million-10.92%
2009 -A$69.28 Million95.77%
2008 -A$35.39 Million
2006 -A$56.69 Million-9.13%
2005 -A$62.39 Million34.74%
2004 -A$46.3 Million36.79%
2003 -A$33.85 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
A$22.27 B 1,280.17%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$10.27 B 536.67%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$7.41 B 359.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-A$0.19 Billion-111.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-A$68.07 Million-104.22%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-A$0.12 Billion-107.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$2.30 B 42.71%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-A$0.23 Billion-114.18%๐Ÿ‡บ๐Ÿ‡ธ USA